PharmaMar's turnover rose 0.8% in H1 2024, reaching €80.8 million, with oncology sales down 3.2%. Royalty income increased by 16%, while non-recurring income slightly declined. R&D...
PharmaMar's profits rebound with a 64% increase to 2.3 million euros in Q1 2024 compared to the same period last year. Total revenues dropped by 19.45%...
PharmaMar started February with falls of almost 3% at the opening of the market. The reason was that Sylentis had failed in its primary objective of...